Syndax Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 184
- Market Cap
- $1.7B
- Introduction
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
Clinical Trials
34
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed KMT2Ar or NUP98r AML (REVEAL-ND KMT2A)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2025-10-08
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 235
- Registration Number
- NCT07212023
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Conditions
- Acute Myeloid Leukemias
- Interventions
- First Posted Date
- 2025-10-08
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 468
- Registration Number
- NCT07211958
Phase 1 Study of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with AML Harboring Alterations in KMT2A/MLL, NPM1, or NUP98 Genes
- Conditions
- Acute Myeloid Leukemias
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Syndax Pharmaceuticals Inc.
- Target Recruit Count
- 22
- Registration Number
- 2024-514531-18-00
- Locations
- 🇺🇸
UCLA Medical Hematology, Burbank, California, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸AdventHealth Blood & Marrow Transplant Center, Orlando, Florida, United States
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 135
- Registration Number
- NCT06132256
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei city, Taiwan
🇦🇺Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺Sunshine Coast University Hospital, Birtinya, Queensland, Australia
Expanded Access Program for Revumenib
- Conditions
- Relapsed/Refractory Acute Leukemia
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Syndax Pharmaceuticals
- Registration Number
- NCT05918913
- Locations
- 🇺🇸
Alabama Center for Childhood Cancer And Blood Disorders, Children's of Alabama, Birmingham, Alabama, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
Charm Therapeutics Raises $80M to Advance AI-Designed Menin Inhibitor for AML Treatment
UK-based Charm Therapeutics secured $80 million in Series B funding to advance its next-generation menin inhibitor for acute myeloid leukemia into Phase I clinical trials starting Q1 2026.
HDAC Inhibitors Market Projected to Surge Through 2034 as Next-Generation Cancer Therapies Advance in Clinical Trials
The HDAC inhibitors market across seven major markets is expected to surge significantly by 2034, driven by innovation in cancer therapies and expanding applications beyond traditional hematologic malignancies.
Syndax Reports Strong Q2 2025 Results with Revuforj Revenue Growth and Pending FDA Approval for NPM1 AML
Syndax Pharmaceuticals reported $28.6 million in Revuforj net revenue for Q2 2025, representing a 43% increase over the first quarter despite approximately one-third of patients pausing treatment for stem cell transplants.
Incyte Reports Strong Q2 2025 Results with Jakafi Growth and New Drug Approvals
Incyte reported strong second quarter 2025 financial results with Jakafi net revenues of $764 million, representing 8% year-over-year growth driven by increased demand across all indications.
Budget Impact Analysis Shows Revumenib Cost-Neutral for Health Plans Despite High Specialty Drug Costs
A recent budget impact analysis demonstrates that revumenib (Revuforj) for relapsed/refractory acute leukemias with KMT2A translocation would be cost-neutral for health plans over three years.
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as New R&D Head and Chief Medical Officer
Dr. Nicholas Botwood joins Syndax Pharmaceuticals from Bristol Myers Squibb, bringing 25 years of oncology drug development and commercialization experience to accelerate the company's cancer therapy pipeline.
Kura Oncology's Menin Inhibitor Ziftomenib Shows Promise in Mid-Stage Cancer Trial
Kura Oncology and Kyowa Kirin report positive results from their Phase 2 clinical trial evaluating ziftomenib, a novel menin inhibitor for cancer treatment.
Syndax Highlights FDA-Approved Therapies and Anticipated Milestones at J.P. Morgan Healthcare Conference
Syndax launched Revuforj (revumenib) for relapsed/refractory acute leukemia with KMT2A translocation, receiving NCCN guideline inclusion for AML and ALL.
Syndax's Revuforj Approved for Leukemia, Biosion Inks $940M Antibody Deal with Aclaris
• Syndax Pharmaceuticals' Revuforj (revumenib) received FDA approval as the first menin inhibitor for relapsed or refractory acute leukemia with specific genetic translocations. • Biosion granted Aclaris Therapeutics exclusive global rights to develop two antibodies, including BSI-045B (anti-TSLP) and BSI-502 (bispecific TSLP/IL4R), for up to $940 million. • Novartis expanded its radiopharma portfolio, licensing a somatostatin receptor 2 radiotherapeutic candidate from Ratio Therapeutics for cancer, potentially worth $745 million plus royalties.
Syndax's Revuforj (revumenib) Receives FDA Approval for KM2A-Rearranged Leukemia
Syndax Pharmaceuticals' Revuforj (revumenib) has gained FDA approval for treating adult and pediatric patients with relapsed or refractory KM2A-rearranged acute myeloid leukemia (AML).